IQUIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IQUIX (IQUIX).
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
| Metabolism | Not extensively metabolized; limited systemic absorption after ophthalmic administration; if absorbed, hepatic metabolism via CYP450 is minimal. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension). |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.5-2.0 L/kg. This suggests extensive tissue distribution, though systemic exposure is low with ophthalmic use. |
| Bioavailability | Ophthalmic administration: systemic bioavailability is low (< 10%) due to absorption through conjunctiva and nasal mucosa; most of the dose is cleared via nasolacrimal drainage. For oral or intravenous routes, bioavailability is not clinically relevant as IQUIX is only approved for ophthalmic use. |
| Onset of Action | For ophthalmic administration, clinical effect (reduction of ocular inflammation) is typically observed within 1-2 hours after instillation. Peak effect occurs around 2-4 hours. |
| Duration of Action | Duration of action is approximately 8-12 hours, consistent with twice-daily dosing. Clinical studies show sustained anti-inflammatory effect throughout the dosing interval. |
| Molecular Weight | 361.37 |
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Children ≥1 year: 1 drop of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1 drop every 4 hours while awake for up to 5 days total. |
| Geriatric use | Same as adult dosing; no specific age-related adjustments, but monitor for ocular adverse effects. |
| 1st trimester | Levofloxacin is generally contraindicated during first trimester due to risk of arthropathy and cartilage damage in animal studies; avoid unless no safer alternative. |
| 2nd trimester | Use only if benefit outweighs risk; fluoroquinolones associated with fetal cartilage damage in animal studies; limited human data. |
| 3rd trimester | Similar to t2; avoid near term due to potential for fetal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for IQUIX (IQUIX).
| Placental transfer | Levofloxacin crosses the placenta; fetal concentrations reach approximately 70-80% of maternal serum levels. |
| Breastfeeding | Levofloxacin is excreted into breast milk in low concentrations; however, due to potential for arthropathy and cartilage damage in nursing infants, alternative agents preferred. Use only if no safer alternative and monitor infant for diarrhea, rash, or joint abnormalities. |
■ FDA Black Box Warning
No FDA black box warning for ophthalmic use. Systemic fluoroquinolones carry a black box warning for tendinitis/tendon rupture, peripheral neuropathy, CNS effects (e.g., seizures, increased intracranial pressure), and exacerbation of myasthenia gravis.
| Serious Effects |
Hypersensitivity to levofloxacin or any quinoloneHistory of tendinopathy with fluoroquinolonesChildren under 18 years (except for specific approved indications)
| Precautions | Do not inject subconjunctivally or introduce into anterior chamber, Prolonged use may result in overgrowth of non-susceptible organisms, including fungi, Hypersensitivity reactions, including anaphylaxis, may occur, Avoid wearing contact lenses during treatment |
| Food/Dietary | No known food interactions with topical ophthalmic levofloxacin. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | IQUIX (levofloxacin) is contraindicated in pregnancy due to the risk of arthropathy and other developmental toxicities observed in animal studies. First trimester: potential for organ malformations; second and third trimesters: increased risk of fetal cartilage damage and other adverse effects. |
| Fetal Monitoring | Maternal: signs of tendonitis, tendon rupture, peripheral neuropathy, CNS effects, QT prolongation, and hypersensitivity reactions. Fetal: ultrasound monitoring for skeletal development and joint integrity if exposure occurs. Periodic assessment for signs of arthropathy in neonates. |
| Fertility Effects | Levofloxacin does not appear to have significant adverse effects on fertility in humans. Animal studies show no impairment of fertility at clinically relevant doses. However, caution is advised in patients planning to conceive due to potential genotoxicity. |
| Clinical Pearls | IQUIX (levofloxacin ophthalmic solution) is a fluoroquinolone antibiotic indicated for bacterial conjunctivitis. Avoid use in patients with known tendon disorders or QT prolongation. Discontinue at first sign of rash or hypersensitivity. Not for injection or oral use. |
| Patient Advice | Do not touch the dropper tip to any surface to avoid contamination. · Wash hands before and after instillation. · Do not wear contact lenses during treatment and for 24 hours after completing therapy. · Discontinue use and contact your doctor if you experience rash, swelling, or severe eye pain. · Wait at least 5 minutes between different eye medications. |